# Dualyx: Research, Ghent, Belgium

> Dualyx: Dualyx is a biotechnology company based in Zwijnaarde, Ghent, Belgium, focused on developing novel therapies for autoimmune diseases.

Source: https://millionrounds.com/startup/dualyx (Millionrounds; every figure on the page links to its filing or article)

Belgium · [Research startup](https://millionrounds.com/companies)

# Dualyx

Dualyx is a biotechnology company based in Zwijnaarde, Ghent, Belgium, focused on developing novel therapies for autoimmune diseases.

Funding reported Last round: Series A

Research Ghent, Belgium

Follow Dualyx and see its new rounds in your feed. [Start following](https://millionrounds.com/login?join=1&why=follow&next=%2Fstartup%2Fdualyx)

Company summary

- **Founded:** 2020 6 years old
- **Team:** 6 1 to 10 people
- **Funding reported:** 43.5M as listed, currency not stated
- **Last round:** Series A May 2023

How sure we are

- ✓ **Listed** We know it exists and what it does
- 2 **Funding reported** A company dataset reports a raise
- 3 **Observed** A filing or a dated announcement confirms a round

No round for Dualyx has been confirmed by a filing or an announcement yet, so nothing here counts toward an investor's record. [How we decide](https://millionrounds.com/methodology)

## About Dualyx

Dualyx is a biotechnology company based in Zwijnaarde, Ghent, Belgium, focused on developing novel therapies for autoimmune diseases.

Founded in 2019 as a spin-off from KU Leuven, Dualyx aims to create next-generation immune modulators that selectively expand regulatory T cells (Tregs) to suppress unwanted autoimmune reactions. The company is led by CEO Wouter Verhoeven and CSO Luc van Rompaey and operates under a collaborative model with partners such as Wurzburg University, Argenx, VIB, Ghent University, and KU Leuven. Dualyx's core technology involves llama-derived antibodies, or nanobodies, to create multi-specific antibodies that target and activate Tregs. This selective action is designed to provide effective immune suppression with minimal side effects. The company is advancing its lead program, DT-001, which targets TNF receptor 2 (TNFR2) and is currently in IND-enabling studies, with plans to enter clinical trials in 2024. Dualyx has raised approximately $52.89M to support its research and development efforts.

## What company datasets say Dualyx raised

Funding, as reported

Reported in all **43.5M** in the source's currency

Rounds **2**

Last round **Series A**

Last round size **44M**

Last round date **May 2023**

Investors listed **9**

## The company, in detail

What they build

Known for

autoimmune disease research health care immune system regulation biotechnology research immune system modulation medical research tnfr2 autoimmunity treatment immune modulating programs antibody agonist treg expansion immune response regulation immune modulators treg in vivo expansion hospital & health care immune suppression

- **Sector:** Research
- **Industry code:** NAICS 541714, 325414, SIC 2834, 8731, 2836
- **Region:** Flanders
- **Revenue:** 1.5M a year, as listed
- **Full record:** [Every detail in the company directory](https://millionrounds.com/directory/dualyx)

## Research in Belgium

Startups like it

- [**Fyteko** Anderlecht · founded 2014 *Raised*](https://millionrounds.com/company/fyteko)
- [**Cellaïon** Mont-Saint-Guibert · founded 2021](https://millionrounds.com/startup/cella-on)
- [**Precirix** Jette · founded 2014](https://millionrounds.com/startup/precirix)
- [**Full-Life Technologies** Gembloux · founded 2021](https://millionrounds.com/startup/full-life-technologies)
- [**Augustine Therapeutics** Leuven · founded 2019](https://millionrounds.com/startup/augustine-therapeutics)
- [**NOVADIP Biosciences S.A.** Mont-Saint-Guibert · founded 2013](https://millionrounds.com/startup/novadip-biosciences-s-a)
- [**EyeD Pharma** Seraing · founded 2012](https://millionrounds.com/startup/eyed-pharma)
- [**atbtherapeutics** Marche-en-Famenne · founded 2018](https://millionrounds.com/startup/atbtherapeutics)

## Is this your company?

Add your raise, your deck and your story, and put Dualyx in front of investors. Or tell us what we have wrong.

[List your startup](https://millionrounds.com/list-your-startup)[Send a correction](https://millionrounds.com/corrections)